Literature DB >> 26333754

Palliative Care Symptom Management.

Sheri M Kittelson1, Marie-Carmelle Elie2, Leslye Pennypacker3.   

Abstract

Aggressively managing the symptoms of patients with critical life-limiting illness or terminal disease can improve the quality of life for patients and loved ones, regardless of how much time they have remaining. Palliative symptom management approaches disease in a holistic manner, addressing not only the physical aspect of symptoms but also the psychological, social, and spiritual dimensions of suffering for total symptom relief. Pain is the most common reason for critical care palliative consultation, and using the World Health Organization Pain Ladder to systematically quantify, treat, and titrate pain is effective. Options include both pharmacologic and nonpharmacologic treatment. Published by Elsevier Inc.

Entities:  

Keywords:  Dyspnea; Hospice; Pain; Palliative care; Symptom management

Mesh:

Year:  2015        PMID: 26333754     DOI: 10.1016/j.cnc.2015.05.010

Source DB:  PubMed          Journal:  Crit Care Nurs Clin North Am        ISSN: 0899-5885            Impact factor:   1.326


  2 in total

1.  Factors Associated with Cancer-Related Pain Requiring High-Dose Opioid Use in Palliative Cancer Patients.

Authors:  Hidetoshi Sumimoto; Komaki Hayashi; Yuri Kimura; Akihito Nishikawa; Seiko Hattori; Chiaki Hasegawa; Hiroaki Morii; Koji Teramoto; Sachiyo Morita; Yataro Daigo
Journal:  Palliat Med Rep       Date:  2021-09-15

2.  Hospitalized patients dying with SARS-CoV-2 infection-An analysis of patient characteristics and management in ICU and general ward of the LEOSS registry.

Authors:  Claudia Raichle; Stefan Borgmann; Claudia Bausewein; Siegbert Rieg; Carolin E M Jakob; Steffen T Simon; Lukas Tometten; Jörg Janne Vehreschild; Charlotte Leisse; Johanna Erber; Melanie Stecher; Berenike Pauli; Maria Madeleine Rüthrich; Lisa Pilgram; Frank Hanses; Nora Isberner; Martin Hower; Christian Degenhardt; Bernd Hertenstein; Maria J G T Vehreschild; Christoph Römmele; Norma Jung
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.